Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy

A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma and in Patients With Adjuvant Nivolumab Therapy

The purpose of this study is to describe the safety and effectiveness of nivolumab treatment, either in monotherapy or in combination with ipilimumab, overall and according to various subgroups of interest, in participants with advanced melanoma and in participants with adjuvant nivolumab therapy.

Inclusion Criteria:

For Cohort 1 and 2: (Recruitment ended by 02/20/2020)

• Advanced melanoma (Stage III/Stage IV)
• Histologically confirmed diagnosis
• Treatment decision for nivolumab monotherapy or nivolumab/ipilimumab combination therapy has already been taken

For Cohort 3: (Recruitment ended by 08/31/2020)

• Primary diagnosis of advanced melanoma after complete surgical tumor resection and no evidence of disease
• Treatment decision for adjuvant nivolumab therapy has already been taken

Exclusion Criteria:

For Cohort 1 and 2: (Recruitment ended by 02/20/2020)

• Current primary diagnosis of a cancer other than advanced melanoma, that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator)
• Previous treatment with nivolumab, for nivolumab monotherapy cohort only
• Current active participation in an interventional clinical trial

For Cohort 3: (Recruitment ended by 08/31/2020)

• Current diagnosis of persisting advanced melanoma or a cancer other than advanced melanoma that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator)
• Current active participation in an interventional clinical trial

Other protocol-defined inclusion/exclusion criteria apply